Aytu BioPharma, Inc. is a pharmaceutical company specializing in the commercialization of novel therapeutics, primarily focusing on prescription products for conditions such as ADHD and pediatric allergies.
In its fiscal 2025 third quarter earnings report, Aytu BioPharma announced a significant financial turnaround, reporting a net income of $4.0 million compared to a net loss in the previous year, alongside a 32% increase in total net revenue.
Key financial highlights include a 25% revenue growth in the ADHD portfolio and a remarkable 77% increase in the pediatric portfolio. The company also achieved an adjusted EBITDA of $3.9 million, reflecting improved operational efficiencies and strategic realignment efforts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.